Alterations associated with NSCLC which are currently well-established

- ALK
- BRAF
- EGFR
- ERBB2
- RET
- KRAS
- MET
- ROS1
- STK11
- NTRK1

Alterations associated with: a) an FDA approved drug for a different tumor type, b) inclusion or exclusion criteria for clinical trials and/or c) indicators for resistance to therapy.

- AKT1
- CCND1
- CDKN2A
- CTNNB1
- ESR1
- FGFR1
- FGFR2
- FGFR3
- GATA3
- GNA11
- GNAQ
- GNAS
- HRAS
- ID1
- IDH2
- KIT
- MAP2K1
- MYC
- NFE2L2
- NRAS
- NTRK3
- PDGFR
- PIK3CA
- PPP2R1A
- PTEN
- TP53
- U2AF1

- SNVs + Indels - Hotspot Regions
- Fusions + SNVs + Indels
- CNVs + SNVs + Indels
- CNVs only
- SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
- Fusions

InVisionFirst®-Lung is a trademark of Inivata Limited
Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer

<table>
<thead>
<tr>
<th>Genomic driver event</th>
<th>Available targeted agents with activity against the genomic driver event in patients with metastatic NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR mutations</td>
<td>afatinib (GILOTRIF®), dacomitinib (VIZIMPRO®), erlotinib + ramucirumab, erlotinib + bevacizumab, erlotinib (TARCEVA®), gefitinib (IRESSA®), osimertinib (TAGRISSO®)</td>
</tr>
<tr>
<td>ALK rearrangements</td>
<td>alectinib (ALCENSA®), brigatinib (ALUNBRIG®), ceritinib (ZYKADIA®), crizotinib (XALKORI®), lorlatinib (LOBRENA®)</td>
</tr>
<tr>
<td>BRAF V600E mutations</td>
<td>dabrafenib (TAFINLAR®) + trametinib (MEKINIST®), vemurafenib (ZELBORAF®)</td>
</tr>
<tr>
<td>ROS1 rearrangements</td>
<td>ceritinib (ZYKADIA®), crizotinib (XALKORI®), entrectinib (ROZLYTREK™)</td>
</tr>
<tr>
<td>NTRK rearrangements</td>
<td>entrectinib (ROZLYTREK™), larotrectinib (VITRAKVI®)</td>
</tr>
<tr>
<td>MET amplifications/mutations</td>
<td>capmatinib (TABRECTA™), crizotinib (XALKORI®)</td>
</tr>
<tr>
<td>RET rearrangements</td>
<td>cabozantinib (COMETRIQ®), selpercatinib (RETEVMO™), vandetanib (CAPRELSA®)</td>
</tr>
<tr>
<td>HER2 mutations</td>
<td>ado-trastuzumab emtansine (KADCYLA®)</td>
</tr>
</tbody>
</table>

Order now to guide your decisions for your advanced NSCLC Patients

USA Toll Free 866.776.5907  Direct outside USA +41 (0)21 721 06 00
neogenomics.com
@NeoGenomics
client.services@neogenomics.com

InVisionFirst®-Lung is a trademark of Inivata Limited. Rev. 062920